CHINESE JOURNAL OF ALLERGY & CLINICAL IMMUNOLOGY RNA Ⅲ * # 100032 SSc RNA Ⅲ ARA SSc 135 SSc ARA SSc ARA 8. 9% 12 7 Ⅰ Scl-70 ACA ARA < 0. 001 2 Rodnan > 0. 05 ARA Scl-70 ACA SSc SSc ARA ARA SSc / RNA Ⅲ R593. 25 R446. 62 A 1673-8705 2011 03-0197-05 Detection of Anti-RNA olymerase III Antibody and Its Association with Clinical Features in Systemic Sclerosis BAI Yi-naHU Chao-junXU DongHOU YongLI Meng-tao ZHAO Jiu-liangSUN Qiu-ning * ZENG Xiao-feng # Department of Rheumatology and Clinical Immunologyeking Union Medical College HospitalChinese Academy of Medical Sciences & eking Union Medical CollegeBeijing 100032China Objective To detect anti-rna polymerase III ARA in sera of SSc patients and to assess its clinical relevance. Methods Immunoblotting assay was used to detect the presence of ARA in sera of 135 Chinese patients with SScwho were prospectively and consecutively enrolled in the study. Association of prevalence of ARA in SSc patients and their clinical characteristics was analyzed. Results ARA was detected in 8. 9% n = 12 of SSc patientsamong whom seven could not detect anti- Scl-70 and anti-centromere antibody ACA. Our series revealed that serum creatinine and blood urea nitrogen level were significantly higher in ARA positive group < 0. 001. Howeverthe association between ARA and clinical features or laboratory findings including modified Rodnan skin scorecardiac pulmonarygastrointestinal or renal involvements were not identified all > 0. 05. Conclusion ARA EULAR Scleroderma Trial and Research GroupEUSTAR 2006BAI01A072008BAI59B02 810724881071300 2009-2003 08010270105 I604900 * 100730 # 010-88068796 zengxiaofeng@ medmail. com. cn 197
may be helpful in diagnosing SScespecially for those anti-scl-70 or ACA can not be detected. ARA positive patients have significantly increased creatinine and blood urea nitrogen level. There is no clinical relevance to other clinical or laboratory features between patients with or without ARA. Chinese SSc patients serological features may be different from other races. Key words sclerodermasystemic /complications autoantibodies anti-rna polymerase III antibody Chin J Allergy Clin Immunol20115 3 197-201 SScEURO line immunoassaylia 1 1 100 1. 5 ml SSc 30 min 3 5 min / ANA 1. 5 ml IgG 30 min Ⅰ Scl-70 3 5 min / 15 min ACA 1993 Okano 1 RNA Ⅲ anti-rna EUROLineScan polymerase III antibodiesara 5 SSc RNA Ⅲ Scl-70 155 000 138 0. 5% Scl-70 000 ARA 4 48 h SSc 4% ~ 22% SSc ENA-6 2 SSc SSc ACA 1 00 30 min IgG 30 min ACA 2009 2010 SSc 135 12 123 38. 2 ± 13. 3 SSc 84. 7 ± 76. 53. 9 ~ 352 1980 3-4 SSc Rodnan 5 1 ARA ARA RNA III 1 Table 1 135 n Clinical manifestations of 135 patients with % ARA ARA 129 11 91. 7 118 95. 9 0. 652 72 6 50 66 53. 7 0. 808 36 3 25. 0 33 26. 8 0. 963 40 3 25. 0 37 30. 1 0. 713 22 4 33. 3 18 14. 6 0. 275 3 1 8. 3 2 1. 6 0. 691 36 3 25. 0 33 26. 8 0. 733 18 1 8. 3 17 13. 8 0. 662 7 1 8. 3 6 4. 9 0. 487 198 September2011
RNA Ⅲ SSS17. 0 ARA x - ± s / χ 2 t 3 < 0. 05 ARA Scl-70 ACA 80. 3 ± 80. 2 > 135 SSc ARA 12 8. 9% Scl-70 67 49. 6% ACA 18 13. 3% ARA Scl-70 7 5. 2% ARA ACA Scl-70 5 ARA ACA Scl-70 1 ARA SSc 3 Table 3 ARA 12 1 135 Cutaneous sclerosis signs of 135 patients with 8. 3% 3 25% 3 n % 25% 1 8. 3% 4 33. 3% 1 8. 3% ARA / 1 ARA 123. 3 ± 169. 0 μmol /L 75. 3 ± 40. 1 μmol /L < 0. 001 7. 9 ± 9. 6 mmol /L 5. 0 ± 2. 21 mmol /L < 65 0. 001 2 2 Table 2 135 4 1 8. 3 3 2. 4 0. 314 Laboratory findings of 135 patients with x ± s ARA ARA mm /h 10. 9 ± 10. 6 20. 4 ± 20. 5 0. 159 C mg /L 4. 1 ± 5. 7 5. 4 ± 8. 9 0. 065 μmol /L 123. 3 ± 169. 0 75. 3 ± 40. 1 < 0. 001 mmol /L 7. 9 ± 9. 6 5. 0 ± 2. 21 < 0. 001 IgG g /L 14. 7 ± 3. 4 16. 3 ± 6. 4 0. 277 IgA g /L 2. 2 ± 1. 0 2. 6 ± 1. 2 0. 414 IgM g /L 1. 2 ± 0. 7 1. 4 ± 0. 7 0. 914 % 73 ± 1 69 ± 9 0. 572 % 97. 5 ± 1. 5 97. 8 ± 2. 3 0. 478 ARA RNA III ARA ARA 92. 7% SSc ARA 56. 4 ± 78. 6 0. 05 1 4 ARA n ARA ARA 88 8 66. 7 80 65. 0 0. 910 56 5 41. 7 51 41. 5 0. 989 123 12 100 111 90. 2 0. 600 30 ARA RNA III Table 4 4 7 58. 3 58 47. 2 0. 552 2 16. 7 28 22. 7 0. 628 135 Measurements of disease progression of 135 patients with n % n ARA ARA 1 21 2 16. 7 19 15. 4 0. 912 1 20 2 16. 7 18 14. 6 0. 692 1 22 4 33. 3 18 14. 6 0. 108 ARA RNA III 199
ARA ARA SSc 5% ~ 23% 6 6 12 SSc 2 7-10 SSc ARA SSc ARA ARA 8. 9% 68 Scl-70 7 ARA SSc / ARA SSc 2 9 1Okano YSteen VDMedsger TA Jret al. Autoantibody reactive with RNA polymerase III in SSc J. Ann Intern Med1993119 1005-1013. SSc 6 9-10 2Koenig MDieudé MSenécal JLet al. redictive value 2% ~ 5% SSc of antinuclear autoantibodies The lessons of the systemic 5 65% 9 13 sclerosis autoantibodies J. Autoimmun Rev20087 588-593. 3Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic 9 12-13 Criteria Committee. reliminary criteria for the 9 ARA 13 classification of scleroderma J. ARA SSc Arthritis Rheum198023 581-590. 4LeRoy ECBlack CFleischmajer Ret al. Scleroderma classificationsubsetsand SSc ARA pathogenesis J. J Rheumatol198815 202-205. 2 SSc 6 10-13 5Clements Lachenbruch Seibold Jet al. Inter-and Scl-70 6 intraobserver variability of total skin thickness score ARA SSc modified Rodnan TSS in J. J ARA SSc Rheumatol199522 1281-1285. 135 6Cavazzana IAngela Caolo Aet al. Anti-RNA polymerase III antibodies A marker of ARA with rapid onset and skin thickening progression J. Autoimmun Rev20098 580-584. 6 14 7Walker UATyndall ACzirják Let al. Geographical variation of disease manifestations in a report from the EULAR Scleroderma Trials and Research SSc EUSTAR group database J. Ann Rheum Dis ARA 200968 856-862. Scl-70 8Faucher BStein Granel Bet al. Low prevalence of 2 5 10 12 15 anti-rna polymerase III antibodies in a French scleroderma population anti-rna polymerase III 200 September2011
RNA Ⅲ scleroderma J. Eur J Intern Med201021 114-117. 9Bussone GBérezné Aestre Vet al. The scleroderma kidney progress in risk factorstherapyand prevention J. Curr Rheumatol Rep201113 37-43. 10Ho KTReveille JD. The clinical relevance of autoantibodies in scleroderma J. Arthritis Res Ther 20035 80-93. 11Grassegger Aohla-Gubo GFrauscher Met al. Autoantibodies in scleroderma clues for clinical evaluationprognosis and pathogenesis J. Wien Med Wochenschr2008 158 19-28. 12Cepeda EJReveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes clinical indications and relevance J. Curr Opin Rheumatol 2004 16 723-732. 13Nihtyanova SIarker JCBlack CMet al. A longitudinal study of anti-rna polymerase III antibody levels in J. Rheumatol200948 1218-1221. 14Ceribelli ACavazzana IAiro at el. Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia GAVE in systemic sclerosis J. J Rheumatol201037 1329-1334. 15Harvey GRButts SRands ALet al. Clinical and serological associations with anti-rna polymerase antibodies in J. Clin Exp Immunol 1999117 395-402. 2011-03-23 201